Nuvectis Pharma Inc’s recent filing unveils that its 10% Owner Mosseri Marlio Charles acquired Company’s shares for reported $44768.0 on Jun 20 ’25. In the deal valued at $7.99 per share,5,603 shares were bought. As a result of this transaction, Mosseri Marlio Charles now holds 2,981,806 shares worth roughly $20.57 million.
Then, Mosseri Marlio Charles bought 28,043 shares, generating $225,746 in total proceeds. Upon buying the shares at $8.05, the 10% Owner now owns 2,976,203 shares.
Before that, Mosseri Marlio Charles bought 5,399 shares. Nuvectis Pharma Inc shares valued at $43,786 were divested by the 10% Owner at a price of $8.11 per share. As a result of the transaction, Mosseri Marlio Charles now holds 2,948,160 shares, worth roughly $20.34 million.
Maxim Group initiated its Nuvectis Pharma Inc [NVCT] rating to a Buy in a research note published on April 02, 2025; the price target was $17. A number of analysts have revised their coverage, including Laidlaw’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. Ladenburg Thalmann began covering NVCT with “Buy” recommendation on July 13, 2022.
Price Performance Review of NVCT
On Tuesday, Nuvectis Pharma Inc [NASDAQ:NVCT] saw its stock fall -5.35% to $6.9. Over the last five days, the stock has lost -8.73%. Nuvectis Pharma Inc shares have risen nearly 11.65% since the year began. Nevertheless, the stocks have risen 27.54% over the past one year.
How much short interest is there in Nuvectis Pharma Inc?
A steep rise in short interest was recorded in Nuvectis Pharma Inc stocks on 2025-07-15, growing by 0.52 million shares to a total of 2.64 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 2.12 million shares. There was a rise of 19.73%, which implies that there is a positive sentiment for the stock.
